title: Assessment of the humoral and cell-mediated immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in highly endemic malarious areas of Papua New Guinea.
abstract: To assess natural immunity against the circumsporozoite (CS) protein and the synthetic vaccine SPf66, immunologic studies were carried out in a highly endemic malarious area of Papua New Guinea. Antibody prevalence, antibody titers, and T cell proliferation against both antigens were measured in 214 adults. Immunologic data were analyzed with respect to longitudinal malariologic and morbidity data. Evidence of genetic traits such as glucose-6-phosphate dehydrogenase deficiency and ovalocytosis was analyzed. Antibody prevalence was high, with 79% and 84% for CS protein and SPf66, respectively, while T cell proliferation was infrequent and low, with 14% and 12% responders, respectively. Anti-CS protein antibodies increased with age but showed no association to malaria indices or morbidity. No protective value was observed with T cell responses or with humoral response to SPf66. These results provide a first description of naturally developed immunity against SPf66 and suggest further studies in to fully understand the mechanism of immunity against this antigen.
authors.affiliation: Papua New Guinea Institute of Medical Research, Madang.
authors.forename: H P
authors.initials: HP
authors.lastname: Beck
authors.forename: I
authors.initials: I
authors.lastname: Felger
authors.forename: S
authors.initials: S
authors.lastname: Kabintik
authors.forename: L
authors.initials: L
authors.lastname: Tavul
authors.forename: B
authors.initials: B
authors.lastname: Genton
authors.forename: N
authors.initials: N
authors.lastname: Alexander
authors.forename: K K
authors.initials: KK
authors.lastname: Bhatia
authors.forename: F
authors.initials: F
authors.lastname: al-Yaman
authors.forename: J
authors.initials: J
authors.lastname: Hii
authors.forename: M
authors.initials: M
authors.lastname: Alpers
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications; D006801:Humans; D007111:Immunity, Cellular; D008137:Longitudinal Studies; D008213:Lymphocyte Activation; D008288:Malaria / Q000150:complications / Q000453:epidemiology / Q000276:immunology*; D017780:Malaria Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D010219:Papua New Guinea / Q000453:epidemiology; D018512:Parasitemia / Q000453:epidemiology / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology*; D015995:Prevalence; D015800:Protozoan Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D012621:Seasons
chemical_list: D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; C041595:circumsporozoite protein, Protozoan